The 2026 Asia-Pacific Excellent Pharmaceutical Award is organized by IMAPAC | BioSupply Chain Asia 2026 within the framework of the Asia Pharmaceutical Supply Chain Conference 2026 event, to honor leading organizations in the fields of biopharmaceutical production, logistics, supply chain management and clinical research in the Asia-Pacific region.
Mr. Salil Chari, FedEx Asia-Pacific Regional Chairman, shared: “We are very honored to receive this recognition – demonstrating the trust that healthcare customers have placed in FedEx. As treatment therapies become more specialized and sensitive to temperatures, logistics requirements also become more stringent. FedEx meets those requirements through a specialized operating system for the life sciences industry, a wide global network and disciplined enforcement procedures, ensuring that each shipment is transported with the highest reliability, transparency and care standards.”
These outstanding capabilities help FedEx become an essential partner in transporting high-value biological drug shipments, including biological products, vaccines, cell and gene therapies, and many other specialized medical products.
The award for FedEx emphasizes the company's ability to deploy services on a large scale, especially in cases that require speed, accuracy and strict temperature assurance. In the context of increasing demand for high-value therapies, along with the expansion of intra-Asian trade channels, FedEx is constantly improving its capacity to ensure the integrity of shipments from laboratories to patients.
For health organizations, research institutes and pharmaceutical manufacturers, FedEx supports safe transportation of time-sensitive and temperature-sensitive products through its International Express network, emergency delivery services (SpS) and global integrated logistics infrastructure.
